Revisiting A Vault Favorite On The Fragile‐Skin Syndrome And The Emerging Role Of Calcipotriene
We’re pulling this article from our JDD vault because it’s one of our most popular reads. First defined in 2007, dermatoporosis describes the gradual breakdown of skin strength due to collagen and elastic-fiber degradation and loss of hyaluronate support. Affecting up to 37.5 percent of adults over 60, primary dermatoporosis from aging and UV exposure—and its secondary form from long-term steroids—manifests as skin atrophy, purpura, pseudoscars, and painful excoriations, with complications ranging from lacerations to deep hematomas. While topical retinoids remain the cornerstone of therapy, this review highlights vitamin D3 analog calcipotriene as a promising adjunct to bolster the extracellular matrix and restore viscoelasticity.
As our population ages, dermatologists can lead the way by routinely assessing skin thickness, via ultrasonography, and fragility in at-risk patients, and by exploring calcipotriene in clinical practice. To transform care for those living with dermatoporosis, let’s champion further research into staging protocols and innovative treatments that go beyond symptom management to rebuild skin resilience.
J Drugs Dermatol. 2024;23(02): doi:10.36849/JDD.0224
Blog write-up assisted by AI
